Clinical trial LUMINOSITY
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | AbbVie |
| EudraCT Identifier | 2018-001772-38 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03539536 |
| Last update |